RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Increased TSH Levels Do Not Affect Safety, Efficacy in Refractory Thyroid Cancer
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 4
SP 15
OP 16
DO 10.1177/1559897715581825
UL http://mdc.sagepub.com/content/15/4/15.abstract
AB In the SELECT trial, lenvatinib treatment of patients with radioactive iodine 131–refractory differentiated thyroid cancer was associated with increased thyroid-stimulating hormone levels. An exploratory analysis found that worst postbaseline thyroid-stimulating hormone levels were not associated with differences in overall safety, progression-free survival, overall survival, or overall response rate.